Tazobactum%25252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin-Tazobactam ## Overview Piperacillin-tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. This combination extends the spectrum of activity of piperacillin to include many beta-lactamase producing bacteria. It is bactericidal. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin structure infections * Community-acquired pneumonia * Hospital-acquired pneumonia (including ventilator-associated pneumonia) * Nosocomial pneumonia ## Adult Dosing The usual dose is 3.375 grams every 6 hours or 4.5 grams every 6 or 8 hours, administered intravenously over at least 30 minutes. Dosing frequency and duration depend on the severity and type of infection and the clinical response. Specific dosing and duration for certain indications may vary based on local protocols. ## Pediatric Dosing * **For patients 2 months of age and older:** Dosing is based on piperacillin weight. * **Complicated intra-abdominal infections:** 100 mg piperacillin/12.5 mg tazobactam per kg of ideal body weight per dose, administered every 8 hours. Maximum dose: 3.375 g per dose. * **Complicated skin and skin structure infections:** 75 mg piperacillin/9.375 mg tazobactam per kg of ideal body weight per dose, administered every 6 hours. Maximum dose: 3.375 g per dose. * **Hospital-acquired pneumonia:** 100 mg piperacillin/12.5 mg tazobactam per kg of ideal body weight per dose, administered every 8 hours. Maximum dose: 4.5 g per dose. * **Note:** Neonates and infants younger than 2 months have immature renal function, and specific dosing recommendations may differ. Consult specific pediatric guidelines. ## Dose Adjustments * **Renal Impairment (CrCl < 40 mL/min):** Adjust dose and/or frequency. For standard dosing of 3.375 g every 6 hours: * CrCl 20-40 mL/min: 2.25 g every 6 hours. * CrCl < 20 mL/min: 2.25 g every 8 hours. * For standard dosing of 4.5 g every 8 hours: * CrCl 20-40 mL/min: 3.375 g every 8 hours. * CrCl < 20 mL/min: 2.25 g every 8 hours. * **Hemodialysis:** Give usual dose with an additional dose after each dialysis. * **Hepatic Impairment:** No dose adjustment is typically needed. ## Contraindications * Known serious hypersensitivity to piperacillin, tazobactam, any other beta-lactam antibiotic, or any component of the formulation. ## Adverse Effects * **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, fever, elevated liver enzymes. * **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures, neutropenia, thrombocytopenia, interstitial nephritis, hemolysis. ## Key Drug Interactions * **Probenecid:** May increase and prolong serum concentrations of piperacillin and tazobactam. * **Neuromuscular Blocking Agents (e.g., vecuronium):** Piperacillin may prolong the action of vecuronium. * **Warfarin:** Monitor INR closely as beta-lactams may potentially decrease warfarin's effect. * **Methotrexate:** Piperacillin may decrease methotrexate clearance; monitor methotrexate levels. * **Aminoglycosides:** Separate administration to avoid potential physical inactivation; however, combination therapy may be synergistic in certain infections. ## Monitoring * Renal function (baseline and periodically, especially in patients with pre-existing renal impairment). * Liver function tests. * Complete blood counts (especially with prolonged therapy). * Signs and symptoms of hypersensitivity reactions. * Signs and symptoms of *C. difficile*-associated diarrhea. ## Clinical Pearls * Piperacillin-tazobactam covers many gram-positive, gram-negative, and anaerobic organisms, including *Pseudomonas aeruginosa*. * Reconstituted solutions should be used within a specific timeframe as per manufacturer instructions. * Avoid concurrent administration with other beta-lactam antibiotics due to the potential for additive toxicity and cross-hypersensitivity. * Monitor for signs of superinfection, especially with prolonged therapy. *** **Disclaimer:** This information is intended for clinical pharmacists and healthcare professionals. It is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines for complete details and to confirm dosage and safety information before making any clinical decisions.